Efficacy and safety of topical PUVA treatment for refractory lesions of mycosis fungoides.

Yan Yan; Chenchen XU; Tao Wang; Jie Liu; Yuehua Liu; Email: Yuehualiu@263net

Return

Efficacy and safety of topical PUVA treatment for refractory lesions of mycosis fungoides.

Author: Yan YAN ¹ ; Chenchen XU ¹ ; Tao WANG ¹ ; Jie LIU ¹ ; Yuehua LIU ² ; Email: YUEHUALIU@263.NET.
Author Information

1. Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2. Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Publication Type:Journal Article
MeSH: Adult; Female; Ficusin; therapeutic use; Humans; Male; Middle Aged; Mycosis Fungoides; drug therapy; pathology; PUVA Therapy; Photosensitizing Agents; therapeutic use; Treatment Outcome
From: Chinese Journal of Oncology 2015;37(11):859-862
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo evaluate the efficacy and safety of topical PUVA treatment of refractory lesions of mycosis fungoides.
METHODSFrom January 2008 to 2014, a total of 10 patients (4 males and 6 females) with mycosis fungoides were treated with topical PUVA in Peking Union Medical College Hospital, including 7 cases in plaque stage and 3 cases in tumor stage. The average number of lesions were 1.9±0.9. The median age of these patients was (46.0±9.4) years. The average course of disease was (12.4±7.7) years. Psoralen was applied topically on treatment area 30 min before total body UVA irradiation treatment, 3 times a week. And the efficiency and safety of the therapy were evaluated.
RESULTSAll the patients were treated with topical PUVA with a median total dose of (161.60±135.96) J/cm2 in an average of (18.10±14.61) fractions. Total dose of UVA was (1 953.25±829.73) J/cm2, and total number of treatment was (261.90±116.79) fractions. The total treatment time was (45.80±26.64) months. Complete clinical response (CR) rate was 60.0%, partial response (PR) rate was 30.0%, and the overall response rate (CR+PR) was 90.0%. One patient showed no response. No severe acute or chronic side effects were observed.
CONCLUSIONTopical PUVA therapy is effective in the treatment of refractory lesions of mycosis fungoides with little severe side effects.